Molecular Targets for Anabolic Bone Therapies

Information

  • Research Project
  • 6989945
  • ApplicationId
    6989945
  • Core Project Number
    R43AG026826
  • Full Project Number
    1R43AG026826-01
  • Serial Number
    26826
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/1/2006 - 18 years ago
  • Project End Date
    2/28/2007 - 17 years ago
  • Program Officer Name
    WILLIAMS, JOHN
  • Budget Start Date
    9/1/2006 - 18 years ago
  • Budget End Date
    2/28/2007 - 17 years ago
  • Fiscal Year
    2006
  • Support Year
    1
  • Suffix
  • Award Notice Date
    8/29/2006 - 18 years ago

Molecular Targets for Anabolic Bone Therapies

[unreadable] DESCRIPTION (provided by applicant): Current literature on the gene expression evaluation of mammalian or human osteoblasts is scant, particularly studies of primary human cells as opposed to animal or cell line investigations. We hypothesize that analysis of gene expression profiles from individual osteogenic growth factors will result in novel gene/ protein networks for each osteogenic growth factors tested. Further, these networks may interact with canonical pathways in new or unique ways, as well as novel intracellular gene/protein networks. Importantly, analysis of both of these may provide new molecular targets for anabolic bone therapies. We further postulate that the analysis of composite cellular gene/protein networks (referred to herein as "super-networks"), constructed from individual osteogenic growth-factor specific networks, will yield common mechanisms important to the processes of bone formation. Velcura Therapeutics, Inc. has pioneered the use of primary human bone cells (preosteoblasts) as targets in novel ex vivo bone formation assays designed to develop therapies that stimulate bone formation for the treatment of bone diseases such as osteoporosis. The intent of this Phase I SBIR is to establish the presence of novel and/or common cellular gene/protein networks, validate their existence, and determine a rank-order of molecular targets for the identification of anabolic bone therapies. Thus, the goals of this SBIR are to determine whether: (1) novel aspects of osteoblast intracellular gene/protein networks can be identified and validated, (2) there are the common intercellular networks utilized during bone formation, and (3) what are the important molecular targets for this process? [unreadable] [unreadable] [unreadable]

IC Name
NATIONAL INSTITUTE ON AGING
  • Activity
    R43
  • Administering IC
    AG
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    273900
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    866
  • Ed Inst. Type
  • Funding ICs
    NIA:273900\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    VELCURA THERAPEUTICS, INC.
  • Organization Department
  • Organization DUNS
    117950324
  • Organization City
    ANN ARBOR
  • Organization State
    MI
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    481085010
  • Organization District
    UNITED STATES